Correction



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 1998 Oct 1;58(5):1084.

Table 1 of the article “Combination Anti-retroviral Therapy for HIV Infection” (June 1998, p. 2791) contained an editing error. Dosing recommendations for zalcitabine (ddC: Hivid) would only include a dose reduction for weight under 60 kg in patients who have developed peripheral neuropathy attributed to zalcitabine therapy. Table 4 of the same article also contained an error. The Invirase formulation of saquinavir should not have been included. The corrected table is reprinted here.

TABLE 4

Summary of Guidelines for Antiretroviral Therapy for HIV Infection

Preferred initial regimen

Two nucleoside analogs + a highly active protease inhibitor, such as ritonavir (Norvir), indinavir (Crixivan), nelfinavir (Viracept) or saquinavir (Fortovase)

Alternative initial regimens

Two nucleoside analogs + a nonnucleoside reverse transcriptase inhibitor

Two nucleoside analogs + saquinavir

Two nucleoside analogs (although not generally recommended)

Regimens not recommended

Monotherapy

Stavudine (Zerit) + zidovudine (Retrovir)

Zalcitabine (Hivid) + didanosine (Videx)

Zalcitabine + stavudine

Zalcitabine + lamivudine (Epivir)

Suggested regimens for patients who fail to respond to initial therapy

• If initial regimen was two nucleoside analogs and a protease inhibitor, change to one of the following:

Two different nucleoside analogs + a different protease inhibitor

Two different nucleoside analogs + a protease inhibitor combination

Two different nucleoside analogs + a protease inhibitor + a nonnucleoside reverse transcriptase inhibitor

• If initial regimen was two nucleoside analogs and a nonnucleoside reverse transcriptase inhibitor, change to the following:

Two different nucleoside analogs + a protease inhibitor

• If initial regimen was two nucleoside analogs, change to the following:

Two different nucleoside analogs + a protease inhibitor

• If initial regimen was one nucleoside analog, change to one of the following:

Two different nucleoside analogs + a protease inhibitor

Two different nucleoside analogs + a nonnucleoside reverse transcriptase inhibitor


note: Recommended nucleoside analog combinations are as follows: zidovudine + lamivudine; zidovudine + didanosine; zidovudine + zalcitabine; stavudine + lamivudine; or didanosine + stavudine.

Information from references 11 and 12.

TABLE 4   Summary of Guidelines for Antiretroviral Therapy for HIV Infection

View Table

TABLE 4

Summary of Guidelines for Antiretroviral Therapy for HIV Infection

Preferred initial regimen

Two nucleoside analogs + a highly active protease inhibitor, such as ritonavir (Norvir), indinavir (Crixivan), nelfinavir (Viracept) or saquinavir (Fortovase)

Alternative initial regimens

Two nucleoside analogs + a nonnucleoside reverse transcriptase inhibitor

Two nucleoside analogs + saquinavir

Two nucleoside analogs (although not generally recommended)

Regimens not recommended

Monotherapy

Stavudine (Zerit) + zidovudine (Retrovir)

Zalcitabine (Hivid) + didanosine (Videx)

Zalcitabine + stavudine

Zalcitabine + lamivudine (Epivir)

Suggested regimens for patients who fail to respond to initial therapy

• If initial regimen was two nucleoside analogs and a protease inhibitor, change to one of the following:

Two different nucleoside analogs + a different protease inhibitor

Two different nucleoside analogs + a protease inhibitor combination

Two different nucleoside analogs + a protease inhibitor + a nonnucleoside reverse transcriptase inhibitor

• If initial regimen was two nucleoside analogs and a nonnucleoside reverse transcriptase inhibitor, change to the following:

Two different nucleoside analogs + a protease inhibitor

• If initial regimen was two nucleoside analogs, change to the following:

Two different nucleoside analogs + a protease inhibitor

• If initial regimen was one nucleoside analog, change to one of the following:

Two different nucleoside analogs + a protease inhibitor

Two different nucleoside analogs + a nonnucleoside reverse transcriptase inhibitor


note: Recommended nucleoside analog combinations are as follows: zidovudine + lamivudine; zidovudine + didanosine; zidovudine + zalcitabine; stavudine + lamivudine; or didanosine + stavudine.

Information from references 11 and 12.


Copyright © 1998 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article